Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Aurinia Pharmaceuticals Inc
AUPH
Healthcare
Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor...
and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:AUPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(12)
•••
ZoranSto
X
Comment by
ZoranSto
on Feb 25, 2021 8:52am
RE:Nothing
Yes I think they are in good shape.....the share price just doesn't want to go up.....I thought we would have more interest.
(40)
•••
jboom70
X
Post by
jboom70
on Feb 25, 2021 8:47am
Nothing
wrong with those earnings,170% increase on sales same period last year. Anyone can see PT's are double current SP. Lets see if we can get a squeeze going, bears have been choking this to death.
Sekur Private Data's Sekur Privacy Communications Solutions Now Available for U.S. Government
posted Mar 09, 2026 9:00am by
Sekur Private Data Ltd.
-
|
Alain Ghiai, CEO of Sekur stated, "This is a significant milestone for Sekur and our U.S. public sector growth strategy. Partnering with i3ICS and securing placement on their GSA MAS contract expands our reach across federal, state, and local agencies seeking modern secure communications capabilities. We're making it easier for government customers to procure and deploy secure communications solutions through a well-established acquisition vehicle. We look forward to supporting mission customers with secure privacy solutions designed to reduce data exposure, enhance confidentiality, and strengthen operational security." ...read more
(40)
•••
jboom70
X
Post by
jboom70
on Feb 19, 2021 7:38am
Short positions
Link LOL If anyone was watching Zacks came out with a article a while ago and with a sell rating on this stock. Then they shorted it to drop the price. Then they accumulated and after put out
...more
(115)
•••
ddogold
X
Comment by
ddogold
on Feb 16, 2021 9:40am
RE:More Upgrades
Took an partial position this morning .
(31)
•••
TrumpThis
X
Post by
TrumpThis
on Feb 11, 2021 5:30pm
Robert Foster started the 1 in 100s chance!
Watch why Voclosporin should be propelling AUP to over $100! Very, very few biotech companies succeed in getting to market. Dr. Robert Foster incorporated Isotechnika Pharma in 1993, where he served
...more
(31)
•••
TrumpThis
X
Post by
TrumpThis
on Feb 08, 2021 3:58pm
Reason for action & jump today?
Up 7% today on good volume. Can anyone expound on the reason? Was a total disappointment that the FDA approval didn't make a greater, lasting SP improvement. Also, anyone know why StockHouse
...more
(40)
•••
jboom70
X
Comment by
jboom70
on Feb 02, 2021 6:08pm
RE:Insider
More buying from another insider.
(5422)
•••
retiredcf
X
Post by
retiredcf
on Feb 01, 2021 11:36am
Globe & Mail
Royal Bank of Canada is backing the country’s largest life sciences venture capital fund in two decades, making it one of the few Bay Street institutions to invest in the surging domestic sector
...more
(40)
•••
jboom70
X
Post by
jboom70
on Feb 01, 2021 5:22am
Insider
Buy, 900 @ 16.14 Stephen Robertson
(5422)
•••
retiredcf
X
Post by
retiredcf
on Jan 29, 2021 11:36am
Streetwise Reports
Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug Source:
...more
(1)
•••
TimeScape
X
Comment by
TimeScape
on Jan 26, 2021 3:13pm
RE:RBC
Thanks for posting the detailed analysis. Product sales estimates are roughly in line with what I was figuring. I said I thought it wouldn't be over $25 Cdn on Monday and it closed at
...more
(12)
•••
ZoranSto
X
Comment by
ZoranSto
on Jan 26, 2021 2:03pm
RE:More Upgrades
With all the strong upgrades I am surprised yesterday's gains did not stick today. I am hoping this goes over $30 cnd over the next few months. GLTA
(5422)
•••
retiredcf
X
Post by
retiredcf
on Jan 26, 2021 7:48am
RBC
All figures are in US$ and their upside scenario target is also raised to US$38. GLTA January 26, 2021 Aurinia Pharmaceuticals Inc. First oral FDA-approved
...more
(5422)
•••
retiredcf
X
Post by
retiredcf
on Jan 26, 2021 7:31am
More Upgrades
Several more analysts on the Street raised their target prices for Aurinia Pharmaceuticals Inc. ( AUPH-Q +26.04%increase , AUP-T +26.71%increase ) in
...more
(5422)
•••
retiredcf
X
Post by
retiredcf
on Jan 26, 2021 6:18am
Top Gainers
Symbol/ Company Price $ Change $ Volume Data delayed at least 15 minutes, as of 25/01/2021 4:15 PM ET | All market data delayed
...more
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Alvopetro 2025 Year End Reserves Includes a 79% Increase in Reserves & Replacement Ratio of 530%
Podcasts